Compare Adaptive Biotechnologies Corp (ADPT) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Star Bulk Carriers Corp — how do they compare? Adaptive Biotechnologies Corp trades at $25.26 (market cap $4.02B), while Star Bulk Carriers Corp trades at $28.37 (market cap $3.11B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Star Bulk Carriers Corp pays a 6.74% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | SBLK | |
|---|---|---|
Market Cap | $4.02B | $3.11B |
Sector | Health | Industrials |
52-Week High | $25.45 | $29.15 |
52-Week Low | $12.30 | $16.79 |
Enterprise Value | $4.08B | $3.79B |
Dividend Yield | — | 6.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
Star Bulk Carriers (SBLK) trades at $27.89, down 1.86% on the day, amid a bullish technical signal and strong fundamental performance. The company reported robust Q2 2026 earnings of $1.21 per share, beating estimates, with net income surging to $144.9 million. Valuation metrics appear attractive with a P/E of 10.85 and EV/EBITDA of 7.46, while profitability improved significantly with a net margin of 23.87% in 2026. Recent news highlights dividend declarations and strong operational results.
Outlook remains positive driven by earnings beats and healthy cash flow, though risks include dry bulk rate volatility and competitive pressures. Analyst consensus is bullish with 14 buy ratings, supporting potential upside, but investors should monitor shipping market cycles and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
